AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

View this $1,675/week 4 bedroom, 2 bathroom rental house at 24 Verona, Surfers Paradise QLD 4217. Available from Friday, 08 August 2025 ...

Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

AbbVie raised its bottom-line guidance for the entirety of 2025. It now believes adjusted net income will amount to $11.88 to $12.08 per share, up from the previous estimate of $11.67 to $11.87.

An encouraging quarterly earnings report was dampened by a new demand from President Trump.

AbbVie expects full-year earnings in the range of $11.88 to $12.08 per share. AbbVie shares have risen 6.5% since the beginning of the year, while the S&P's 500 index has risen 8%.

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people familiar with the matter, highlighting growing interest in a controversial ...

AbbVie expects full-year earnings in the range of $11.88 to $12.08 per share. AbbVie shares have risen 6.5% since the beginning of the year, while the S&P’s 500 index has risen 8%.